Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

176
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
176
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: Implications for perioperative hemostatic assessment.

Transfusion·2026
Same author

A global survey of blood transfusion practices for patients with sickle cell disease.

Transfusion·2026
Same author

Alpha-Gal Syndrome: Unrecognized Risks of a Tick-Bite-Associated Allergy in Transplantation and Cellular Therapy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

AABB survey on directed blood donation practices.

Transfusion·2026
Same author

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
Same author

A survey of transfusion support strategies for passenger lymphocyte syndrome in minor ABO-mismatched allogeneic hematopoietic stem cell transplantation.

Transfusion·2026

相关实验视频

Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K

在产后出血中补充XIII因子:从生物学理由到临床实施

Jeremy W Jacobs1,2, Elizabeth A Abels3, Brian D Adkins4

  • 1Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.

American journal of hematology
|December 31, 2025
PubMed
概括

早期补充XIII因子可能会降低产后出血 (PPH) 的孕产妇死亡率. 这项研究调查了FXIII.

更多相关视频

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

相关实验视频

Last Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

科学领域:

  • 产科和妇科 产科和妇科
  • 血液学 血液学 血液学
  • 翻译医学是一种翻译医学.

背景情况:

  • 产后出血 (PPH) 是可预防的孕产妇死亡的主要原因.
  • 标准干预和纤维素原试验在降低PPH相关死亡率方面取得了有限的成功.
  • 凝血因子XIII (FXIII) 的活性在怀孕和PPH期间下降,这表明它在血液静止中起作用.

研究的目的:

  • 评估早期FXIII补充剂在管理PPH中的有效性.
  • 调查FXIII作为PPH的潜在治疗剂.
  • 为了解决改善PPH干预措施的未满足需求.

主要方法:

  • SWIFT试验 (NCT06481995) 是第一项针对PPH早期FXIII补充剂的随机对照试验.
  • 观察性研究表明,低产前FXIII预测出血风险.
  • 活体研究表明,FXIII补充剂恢复了凝块的牢固性.

主要成果:

  • 观察数据表明,低水平的FXIII与增加的出血风险有关.
  • 活体实验表明,FXIII补充剂增强了凝块的稳定性.
  • 目前正在进行SWIFT试验,评估PPH患者早期FXIII的使用情况.

结论:

  • FXIII在稳定血栓方面发挥着至关重要的作用.
  • 早期的FXIII补充是改善PPH结果的有希望的策略.
  • 解决实施挑战对于成功地在PPH管理中采用FXIII疗法至关重要.